Monday, June 10, 2013

• BioLineRx Enters into Collaboration to Develop and Commercialize Hepatitis C Drug with CTTQ, Leading Chinese Pharma Company for Liver Disease TherapeuticsBusiness Wire( (Mon, Jun 10)

Thursday, June 6, 2013

• BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BL-8040, for Treatment of LeukemiaBusiness Wire( (Thu, Jun 6)

Friday, May 17, 2013

• BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel, Nicolaus & CompanyBusiness Wire( (Fri, May 17)

Thursday, May 9, 2013

• BioLineRx to Present at the Oppenheimer 14th Annual Israeli Conference on May 12thBusiness Wire( (Thu, May 9)

Tuesday, May 7, 2013

• BioLineRx Reports First Quarter 2013 ResultsBusiness Wire( (Tue, May 7)

Thursday, May 2, 2013

• BioLineRx's BL-7010, for the Treatment of Celiac, to be Presented at Two Leading ConferencesBusiness Wire( (Thu, May 2)

Tuesday, April 30, 2013

• BioLineRx to Report First Quarter 2013 Results on May 7, 2013Business Wire( (Tue, Apr 30)

Monday, April 29, 2013

• BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis CBusiness Wire( (Mon, Apr 29)

Thursday, April 18, 2013

• BioLineRx to Present at the 12th Annual Needham Healthcare Conference in New York on April 30, 2013Business Wire( (Thu, Apr 18)

Wednesday, April 17, 2013

• BioLineRx Announces Positive Phase II Results for BL-7040, an Orally Available Treatment for Inflammatory Bowel DiseaseBusiness Wire( (Wed, Apr 17)

Tuesday, April 16, 2013

• Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business DevelopmentPR Newswire( (Tue, Apr 16)

Wednesday, April 10, 2013

• BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial for BL-8040, for Treatment of LeukemiaBusiness Wire( (Wed, Apr 10)

Wednesday, March 20, 2013

• BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for SchizophreniaBusiness Wire( (Wed, Mar 20)